Generate Biomedicines, Inc.
GENB
Rank in Stocks
#6261
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative... Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Share Price
$14.18
Last synced: 2026-11-09
Market Cap
$1.82B
Change (1 day)
8.58%
Change (1 year)
-
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Generate Biomedicines, Inc. (GENB)
Category
Healthcare
EPS for Generate Biomedicines, Inc. (GENB)
EPS as of June 2026 TTM: $-1.06
According to Generate Biomedicines, Inc.'s latest financial reports, its current EPS (TTM) is $-1.06. At the end of 2025 the company had an EPS of $-4.98, a decrease compared to its 2024 EPS of $-1.68.
EPS history for Generate Biomedicines, Inc. from 2024 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.06 | -78.71% |
| 2025 | $-4.98 | 196.43% |
| 2024 | $-1.68 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,577.36% |
US
|
|
| $-7.07 | 566.98% |
US
|
|
| $-5.29 | 399.06% |
AU
|
|
| $12.88 | -1,315.10% |
BE
|
|
| $21.56 | -2,133.96% |
NL
|
Questions about Generate Biomedicines, Inc.'s earnings per share (EPS)
What is Generate Biomedicines, Inc.'s earnings per share (EPS)?
Generate Biomedicines, Inc.'s earnings per share (EPS) over the last twelve months is $-1.06, as of Jun 2026.
What was Generate Biomedicines, Inc.'s earnings per share (EPS) in 2025?
In 2025, Generate Biomedicines, Inc.'s earnings per share (EPS) was $-4.98, compared with $-1.68 in 2024.
How does Generate Biomedicines, Inc.'s earnings per share (EPS) compare with similar companies?
Generate Biomedicines, Inc.'s earnings per share (EPS) ($-1.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.